To investigate the effect of probiotics on intestinal flora in the eradication of helicobacter pylori based on high-throughput sequencing technology

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034524

Enrollment

Unknown

Registered

2020-07-08

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal flora

Interventions

experimental group:Bifidobacterium triplex live bacteria capsule

control group:Standard quadruple therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients and healthy volunteers who visited Shapingba District People's Hospital due to gastrointestinal symptoms were definitely diagnosed as HP infection by carbon 14 breath test or rapid urease test.

Exclusion criteria

Exclusion criteria: (1) Received the following drugs within 4 weeks, including proton pump inhibitors, antibiotics, H2 receptor antagonists, hormones, bismuth agents, or non-steroidal anti-inflammatory drugs; (2) Probiotics within 4 weeks; (3) Previous history of gastrointestinal surgery; (4) Malignant diseases of the blood system or diseases of connective tissue; (5) Infectious disease within 2 weeks. (6) History of alcohol abuse, diabetes or other problems affecting intestinal flora.

Design outcomes

Primary

Measure	Time frame
Microbial diversity;	—

Countries

China

Contacts

Public ContactTingting Jiang

People's Hospital of Shapingba District of Chongqing

1539889961@qq.com+86 19923717864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026